• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在鼻腔黏膜分泌物中,严重和轻度 SARS-CoV-2 感染中存在不同的 IFN 和 IgA 反应。

In Nasal Mucosal Secretions, Distinct IFN and IgA Responses Are Found in Severe and Mild SARS-CoV-2 Infection.

机构信息

Post-graduation Program in Sciences of Human Movement and Rehabilitation, Federal University of São Paulo, São Paulo, Brazil.

Laboratory of Clinical and Molecular Virology, Department of Microbiology, Institute of Biomedical Science of University of São Paulo, São Paulo, Brazil.

出版信息

Front Immunol. 2021 Feb 25;12:595343. doi: 10.3389/fimmu.2021.595343. eCollection 2021.

DOI:10.3389/fimmu.2021.595343
PMID:33717074
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7946815/
Abstract

Likely as in other viral respiratory diseases, SARS-CoV-2 elicit a local immune response, which includes production and releasing of both cytokines and secretory immunoglobulin (SIgA). Therefore, in this study, we investigated the levels of specific-SIgA for SARS-CoV-2 and cytokines in the airways mucosa 37 patients who were suspected of COVID-19. According to the RT-PCR results, the patients were separated into three groups: negative for COVID-19 and other viruses (NEGS, = 5); negative for COVID-19 but positive for the presence of other viruses (OTHERS, = 5); and the positive for COVID-19 (COVID-19, = 27). Higher specific-SIgA for SARS-CoV-2, IFN-β, and IFN-γ were found in the COVID-19 group than in the other groups. Increased IL-12p70 levels were observed in OTHERS group as compared to COVID-19 group. When the COVID-19 group was sub stratified according to the illness severity, significant differences and correlations were found for the same parameters described above comparing severe COVID-19 to the mild COVID-19 group and other non-COVID-19 groups. For the first time, significant differences are shown in the airway's mucosa immune responses in different groups of patients with or without respiratory SARS-CoV-2 infection.

摘要

可能与其他病毒性呼吸道疾病一样,SARS-CoV-2 会引发局部免疫反应,包括细胞因子和分泌型免疫球蛋白(SIgA)的产生和释放。因此,在这项研究中,我们调查了 37 例疑似 COVID-19 的患者气道黏膜中针对 SARS-CoV-2 的特异性 SIgA 和细胞因子的水平。根据 RT-PCR 结果,将患者分为三组:COVID-19 和其他病毒均为阴性(NEGS,n=5);COVID-19 为阴性但存在其他病毒(OTHERS,n=5);COVID-19 为阳性(COVID-19,n=27)。与其他组相比,COVID-19 组的针对 SARS-CoV-2 的特异性 SIgA、IFN-β 和 IFN-γ 水平更高。与 COVID-19 组相比,OTHERS 组的 IL-12p70 水平升高。当根据疾病严重程度对 COVID-19 组进行分层时,与轻度 COVID-19 组和其他非 COVID-19 组相比,严重 COVID-19 组与上述所有参数均存在显著差异和相关性。这是首次显示出在有或没有呼吸道 SARS-CoV-2 感染的不同患者组中,气道黏膜免疫反应存在显著差异。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/212e/7946815/afde6cafb44a/fimmu-12-595343-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/212e/7946815/eb33a1956999/fimmu-12-595343-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/212e/7946815/8ed9b6e1eb68/fimmu-12-595343-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/212e/7946815/afde6cafb44a/fimmu-12-595343-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/212e/7946815/eb33a1956999/fimmu-12-595343-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/212e/7946815/8ed9b6e1eb68/fimmu-12-595343-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/212e/7946815/afde6cafb44a/fimmu-12-595343-g0003.jpg

相似文献

1
In Nasal Mucosal Secretions, Distinct IFN and IgA Responses Are Found in Severe and Mild SARS-CoV-2 Infection.在鼻腔黏膜分泌物中,严重和轻度 SARS-CoV-2 感染中存在不同的 IFN 和 IgA 反应。
Front Immunol. 2021 Feb 25;12:595343. doi: 10.3389/fimmu.2021.595343. eCollection 2021.
2
Distinct Immunological Profiles Help in the Maintenance of Salivary Secretory IgA Production in Mild Symptoms COVID-19 Patients.不同的免疫特征有助于维持 COVID-19 轻症患者的唾液分泌型免疫球蛋白 A 产生。
Front Immunol. 2022 May 24;13:890887. doi: 10.3389/fimmu.2022.890887. eCollection 2022.
3
Detection of SARS-CoV-2-Specific Secretory IgA and Neutralizing Antibodies in the Nasal Secretions of Exposed Seronegative Individuals.在血清阴性暴露个体的鼻腔分泌物中检测到 SARS-CoV-2 特异性分泌型 IgA 和中和抗体。
Viruses. 2024 May 27;16(6):852. doi: 10.3390/v16060852.
4
Natural mucosal barriers and COVID-19 in children.儿童的天然黏膜屏障与 COVID-19。
JCI Insight. 2021 May 10;6(9):148694. doi: 10.1172/jci.insight.148694.
5
Mild Cytokine Elevation, Moderate CD4 T Cell Response and Abundant Antibody Production in Children with COVID-19.儿童 COVID-19 患者表现为轻度细胞因子升高、中度 CD4+T 细胞应答和丰富的抗体产生。
Virol Sin. 2020 Dec;35(6):734-743. doi: 10.1007/s12250-020-00265-8. Epub 2020 Jul 22.
6
Symptoms and immunoglobulin development in hospital staff exposed to a SARS-CoV-2 outbreak.接触 SARS-CoV-2 疫情的医院工作人员的症状和免疫球蛋白发展情况。
Pediatr Allergy Immunol. 2020 Oct;31(7):841-847. doi: 10.1111/pai.13278. Epub 2020 Jun 18.
7
Delayed Mucosal Antiviral Responses Despite Robust Peripheral Inflammation in Fatal COVID-19.尽管 COVID-19 患者存在强烈的外周炎症,但黏膜抗病毒反应延迟。
J Infect Dis. 2024 Jul 25;230(1):e17-e29. doi: 10.1093/infdis/jiad590.
8
Age-Related Expression of IFN-λ1 IFN-I and Beta-Defensins in the Nasopharynx of SARS-CoV-2-Infected Individuals.年龄相关性 IFN-λ1、IFN-I 和 β 防御素在 SARS-CoV-2 感染个体鼻咽部的表达。
Front Immunol. 2021 Nov 10;12:750279. doi: 10.3389/fimmu.2021.750279. eCollection 2021.
9
Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19.SARS-CoV-2 感染和 COVID-19 康复过程中抗 SARS-CoV-2 抗体的动态变化。
Nat Commun. 2020 Nov 27;11(1):6044. doi: 10.1038/s41467-020-19943-y.
10
Longitudinal Analysis of Inflammatory Response to SARS-CoV-2 in the Upper Respiratory Tract Reveals an Association with Viral Load, Independent of Symptoms.上呼吸道对 SARS-CoV-2 炎症反应的纵向分析显示,与症状无关,与病毒载量有关。
J Clin Immunol. 2021 Nov;41(8):1723-1732. doi: 10.1007/s10875-021-01134-z. Epub 2021 Sep 28.

引用本文的文献

1
Positive Role of Saliva in the Oral Microbiome.唾液在口腔微生物群中的积极作用。
Adv Exp Med Biol. 2025;1472:103-118. doi: 10.1007/978-3-031-79146-8_7.
2
Bacterial lysates in modifying sIgA levels in the upper respiratory tract in COVID-19 patients.细菌裂解物对新冠病毒肺炎患者上呼吸道中分泌型免疫球蛋白A水平的影响
Sci Rep. 2025 Mar 10;15(1):8325. doi: 10.1038/s41598-025-92794-z.
3
Salivary assessment of the immune/inflammatory responses and oxidative stress in older adults vaccinated with CoronaVac or ChadOx-1.CoronaVac 或 ChadOx-1 疫苗接种老年人唾液免疫/炎症反应和氧化应激评估

本文引用的文献

1
Protective Potentials of Type III Interferons in COVID-19 Patients: Lessons from Differential Properties of Type I- and III Interferons.III型干扰素在新冠患者中的保护作用:从I型和III型干扰素的差异特性中汲取的经验教训
Viral Immunol. 2021 Jun;34(5):307-320. doi: 10.1089/vim.2020.0076. Epub 2020 Nov 4.
2
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients.严重 COVID-19 患者的 I 型干扰素活性和炎症反应受损。
Science. 2020 Aug 7;369(6504):718-724. doi: 10.1126/science.abc6027. Epub 2020 Jul 13.
3
Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors.
BMC Geriatr. 2024 Oct 3;24(1):807. doi: 10.1186/s12877-024-05357-8.
4
Unravelling the role of secretory Immnuoglobulin-A in COVID-19: a multicentre study in nursing homes during the first wave.揭示分泌型免疫球蛋白A在2019冠状病毒病中的作用:首波疫情期间养老院的多中心研究
BMC Geriatr. 2024 Oct 1;24(1):804. doi: 10.1186/s12877-024-05402-6.
5
Uncovering the Contrasts and Connections in PASC: Viral Load and Cytokine Signatures in Acute COVID-19 versus Post-Acute Sequelae of SARS-CoV-2 (PASC).揭示新冠后综合征(PASC)中的差异与联系:急性新冠肺炎与新冠病毒2型(SARS-CoV-2)急性后遗症中的病毒载量和细胞因子特征
Biomedicines. 2024 Aug 23;12(9):1941. doi: 10.3390/biomedicines12091941.
6
Investigation of Nasal Mucosal IgA Responses in the Population Following COVID-19 Pandemic - China, September 2022-August 2023.2022年9月至2023年8月中国新冠疫情后人群鼻黏膜IgA反应的调查
China CDC Wkly. 2024 Apr 12;6(15):312-317. doi: 10.46234/ccdcw2024.060.
7
Impact of social distancing from the COVID-19 pandemic on the immuno-inflammatory response of older adults.新冠疫情期间社交距离措施对老年人免疫炎症反应的影响。
BMC Geriatr. 2024 Jan 26;24(1):99. doi: 10.1186/s12877-024-04699-7.
8
Development of an Oral IgA Response against SARS-CoV-2 Following Immunization with Different COVID-19 Vaccines.接种不同 COVID-19 疫苗后针对 SARS-CoV-2 产生的口服 IgA 应答的发展。
Viruses. 2023 Nov 25;15(12):2319. doi: 10.3390/v15122319.
9
Utility of nasal swabs for assessing mucosal immune responses towards SARS-CoV-2.鼻拭子在评估针对 SARS-CoV-2 的黏膜免疫反应中的效用。
Sci Rep. 2023 Oct 19;13(1):17820. doi: 10.1038/s41598-023-44989-5.
10
SARS-CoV-2 hijacks neutralizing dimeric IgA for nasal infection and injury in Syrian hamsters.SARS-CoV-2 劫持中和二聚体 IgA 以感染和损伤叙利亚仓鼠鼻腔。
Emerg Microbes Infect. 2023 Dec;12(2):2245921. doi: 10.1080/22221751.2023.2245921.
分析 COVID-19 患者的血清细胞因子表明,IL-6 和 IL-10 是疾病严重程度的预测因子。
Emerg Microbes Infect. 2020 Dec;9(1):1123-1130. doi: 10.1080/22221751.2020.1770129.
4
Interferons in the Therapy of Severe Coronavirus Infections: A Critical Analysis and Recollection of a Forgotten Therapeutic Regimen with Interferon Beta.干扰素在重症冠状病毒感染治疗中的应用:对一种被遗忘的干扰素β治疗方案的批判性分析与回顾
Drug Res (Stuttg). 2020 Jul;70(7):291-297. doi: 10.1055/a-1170-4395. Epub 2020 May 22.
5
Emerging pharmacotherapies for COVID-19.用于治疗 COVID-19 的新兴药物疗法。
Biomed Pharmacother. 2020 Aug;128:110267. doi: 10.1016/j.biopha.2020.110267. Epub 2020 May 14.
6
The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response.癌症免疫治疗学会对 COVID-19 相关全身炎症反应中白细胞介素-6 信号转导的调控观点。
J Immunother Cancer. 2020 May;8(1). doi: 10.1136/jitc-2020-000930.
7
Immune environment modulation in pneumonia patients caused by coronavirus: SARS-CoV, MERS-CoV and SARS-CoV-2.冠状病毒(SARS-CoV、MERS-CoV和SARS-CoV-2)所致肺炎患者的免疫环境调节
Aging (Albany NY). 2020 May 2;12(9):7639-7651. doi: 10.18632/aging.103101.
8
Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients.SARS-CoV-2 感染患者外周血淋巴细胞反应和细胞因子谱的纵向特征。
EBioMedicine. 2020 May;55:102763. doi: 10.1016/j.ebiom.2020.102763. Epub 2020 Apr 18.
9
COVID-19: a case for inhibiting IL-17?COVID-19:抑制白细胞介素-17(IL-17)的理由?
Nat Rev Immunol. 2020 Jun;20(6):345-346. doi: 10.1038/s41577-020-0328-z.
10
COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options.COVID-19 与心血管系统:对风险评估、诊断和治疗选择的影响。
Cardiovasc Res. 2020 Aug 1;116(10):1666-1687. doi: 10.1093/cvr/cvaa106.